Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
The late-breaking abstract details results from the Heparc-2001, Phase 2 study of ARC-520 in combination with entecavir (ETV). Key findings include the following:
- Naïve patients reduced viral DNA up to 4.3 log (mean 2.2 log)
- Naïve e-antigen (HBeAg) positive patients reduced surface antigen (HBsAg) up to 1.9 log (mean max 1.1 log)
- ARC-520 reduced HBeAg up to 1.7 log (mean max 1.2 log)
- ARC-520 therapy was well tolerated with no adverse events rated serious, severe, drug-related or causing withdrawal from the trial
- 15 patients are continuing in follow-up and additional results may be available to report at The Liver Meeting
With the addition of the late-breaking poster, Arrowhead has the following three abstracts accepted for presentation at the Liver Meeting:
Additional details including presentation abstracts can be found on the AASLD website by clicking this link. A copy of presentation materials can be accessed by visiting the Events section of the Arrowhead website after the presentations conclude.
About ARC-520
Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. Arrowhead has completed a Phase 1 single ascending dose study in normal volunteers and the company is conducting single dose Phase 2a studies and multiple dose Phase 2b studies in chronic HBV patients. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally.
About
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, rapid technological change in our markets, and the enforcement
of our intellectual property rights.
DYNAMIC POLYCONJUGATES is a trademark of
The Liver Meeting is a registered trademark of the
Source:
View source version on businesswire.com: http://www.businesswire.com/news/home/20151020005585/en/
626-304-3400
ir@arrowres.com
or
Investor
Relations:
ir@arrowres.com
or
Media:
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com
Source:
News Provided by Acquire Media